Acceleron Pharma (XLRN) Misses Q4 EPS Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights
February 25, 2016 7:00 AM EST- Initiated Phase 3 trials with luspatercept in MDS and beta-thalassemia with partner Celgene -
- Received Fast Track Designation for luspatercept in MDS and beta-thalassemia, and for dalantercept in RCC -
- Presented initial Phase 1 results for ACE-083, a locally acting therapeutic candidate for muscle diseases -
- Introduced ACE-2494, Acceleron's first IntelliTrap molecule, a therapeutic candidate for systemic muscle diseases -
- Raised $150 million in gross proceeds to advance wholly owned programs, including locally acting and systemic agents for muscle diseases... More
